Dergiler / Medicine Science / 2016 / Cilt: 5 - Sayı: 1

Safety and efficacy of Methotrexate Monotherapy Vs Methotrexate plus Leflunomide Combination Therapy in Early Active Rheumatoid Arthritis Patients

Sayfa
117–133
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Taken into consideration proper monitoring of liver toxicity, this combination is safe and more effectively intervene early in the disease process thus preventing future possible complications and aiming better remission

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:MTX has long been considered as the anchor drug in RA treatment, however given, its high failure rate and the multifactorial nature of the disease, there has been a great interest in developing more powerful and tolerable MTX combination therapies.
📊
Temel Bulgular & Veri:Fifty female patients with early active RA were randomly allotted in two groups each of 25.
💡
Sonuç & Katkı:Taken into consideration proper monitoring of liver toxicity, this combination is safe and more effectively intervene early in the disease process thus preventing future possible complications and aiming better remission
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

MTX has long been considered as the anchor drug in RA treatment, however given, its high failure rate and the multifactorial nature of the disease, there has been a great interest in developing more powerful and tolerable MTX combination therapies. Leflunomide has long been appreciated to be a suitable alternative therapy used on its own or with MTX due to its equivalent efficacy and structural similarity. The aim of the study was to compare the efficacy and safety of a combination therapy of MTX plus LEF to MTX alone when used with early active rheumatoid arthritis patients. Fifty female patients with early active RA were randomly allotted in two groups each of 25. Patients were randomized to receive MTX or MTX+LEF. Analysis of DAS28 score, complete blood picture, and liver enzymes at the start and post 24 weeks of treatment with study regimens was performed, compared and evaluated. MTX+LEF combination therapy was more significantly beneficial in decreasing DAS28 score compared to MTX alone. The combination therapy showed less effect on blood components, but was more hepatotoxic compared to MTX monotherapy. The combination therapy is a more attractive option to consider especially in early active RA patients than MTX monotherapy. It is more clinically beneficial in improving disease outcomes, well tolerated, with less hematological toxicity and only showed mild hepatotoxicity. Taken into consideration proper monitoring of liver toxicity, this combination is safe and more effectively intervene early in the disease process thus preventing future possible complications and aiming better remission

🔖

Bu Makaleye Atıf Yap

BOSHRA, M. S., AHMED, A. S., SALEM, H. F., HAMİD, M. N. A. E. (2016). Safety and efficacy of Methotrexate Monotherapy Vs Methotrexate plus Leflunomide Combination Therapy in Early Active Rheumatoid Arthritis Patients. Medicine Science, Cilt: 5 - Sayı: 1, 117–133. https://ajindex.com/articles/277521

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19
  2. Ding CZ, Yao Y, Feng XB, Fang Y, Zhao C, Wang Y. Clinical analysis of chinese patients with rheumatoid arthritis treated with leflunomide and methotrexate combined with different dosages of glucocorticoid. Curr Ther Res Clin Exp. 2012;73(4-5):123-33
  3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, RubbertRoth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509
  4. Van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009;5(10):531-41
  5. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-82
  6. Dale J, Alcorn N, Capell H, Madhok R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol. 2007;3(8):450-8; quiz, following 478
  7. Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis.Clin Ther. 2004;26(4):447-59
  8. Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol. 2011;23(3):288-92
  9. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8. 10. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Agains